A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00571675 | Completed Phase 2

• 1 other identifier: AT-101-CS-205
• Study Type: interventional
• Target: 220
• Locations: 2 countries
• Sites: 35

Brief Summary

This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.

Conditions

Hormone Refractory Prostate Cancer

Keywords

Prostate Cancer; Hormone Refractory Prostate Cancer; HRPC; Docetaxel; Taxotere; Prednisone; Metastatic (Stage IV) Disease; Chemotherapy-naïve metastatic Hormone Refractory Prostate Cancer (HRPC)

Outcome Measures

Primary Outcomes (1)

• To evaluate and compare the two treatment arms with respect to overall survival (OS)

  33 months

Secondary Outcomes (3)

• To evaluate and compare progression-free survival (PFS) in men with chemotherapy-naïve metastatic HRPC treated with AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo.

  33 months

• To determine the toxicities associated with oral AT-101 administered in combination with docetaxel and prednisone.

  28 months

• To evaluate PSA and objective tumor response rate.

  28 months

Study Arms (2)

1

EXPERIMENTAL

AT-101, prednisone and docetaxel

Drug: AT-101, prednisone and docetaxel

2

PLACEBO COMPARATOR

Placebo, prednisone and docetaxel

Drug: placebo, prednisone and docetaxel

Interventions

AT-101, prednisone and docetaxel DRUG

docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3

1

placebo, prednisone and docetaxel DRUG

docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3

2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males age ≥ 18 years with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g. any T, any N, M1a-c) based on bone scan, CT scan, or MRI scan.
• Progression of disease despite androgen deprivation (androgen ablation or surgical castration) and anti-androgen withdrawal as documented by one or more of the following.
• Progression of measurable disease per RECIST
• Bone scan progression, defined as the appearance of ≥ 2 new lesions on bone scan, attributable to prostate cancer
• Rising PSA, as defined by increasing levels on at least two consecutive assessments, following a prior assessment taken as a reference value, where all of the following are met:
• The assessments are at least one week apart, with the first assessment at least one week later than the reference value
• Progressive increase in the two assessments after the reference value, without an intervening decrease between assessments.
• The last value prior to study entry is ≥ 2 ng/mL
• Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist.
• At least 2 weeks since ketoconazole or systemic steroids (any dose); 2 weeks since prior flutamide, megestrol, or aminoglutethimide; and at least 2 weeks since prior bicalutamide or nilutamide
• Radiation therapy and/or therapy with samarium must have been completed 4 weeks prior to first dose of therapy. Strontium therapy must have been completed at least 12 weeks prior to the first dose of therapy. The patient must have recovered from all treatment-related toxicities.
• ECOG performance status ≤ 2
• Able to swallow and retain oral medication

You may not qualify if:

• Received prior chemotherapy (including estramustine phosphate \[Estracyt\]) for HRPC. Adjuvant chemotherapy (including docetaxel) is allowed provided that progression of disease occurred ≥ 6 months after the completion of adjuvant therapy.
• Patients must not be receiving concurrent anti-androgen hormonal therapy for HRPC (LHRH directed therapies are acceptable to maintain castrate levels of testosterone).
• Treatment with monoclonal antibody (e.g., VEGF targeting antibody) or prostate cancer vaccine within 45 days prior to the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤ 1.
• Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis
• Active secondary malignancy or history of other malignancy within the last 5 years
• Prior history of radiation therapy to ≥ 30% of the bone marrow
• Peripheral neuropathy of ≥ Grade 2
• Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction are also excluded.
• Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
• Known active symptomatic fungal, bacterial and/or viral infection including active HIV. Note: screening for viruses is not required.
• Psychiatric illness/social situations that would limit compliance with the study requirements.

Sponsors & Collaborators

• Ascenta Therapeutics: lead

Study Sites (35)

Unknown Facility

Colorado Springs, Colorado, United States

Location

Unknown Facility

New Port Richey, Florida, United States

Location

Unknown Facility

Ocoee, Florida, United States

Location

Unknown Facility

Fishers, Indiana, United States

Location

Unknown Facility

Burnsville, Minnesota, United States

Location

Unknown Facility

Las Vegas, Nevada, United States

Location

Unknown Facility

Albuquerque, New Mexico, United States

Location

Unknown Facility

Las Cruces, New Mexico, United States

Location

Unknown Facility

Raleigh, North Carolina, United States

Location

Unknown Facility

Kettering, Ohio, United States

Location

Unknown Facility

Eugene, Oregon, United States

Location

Unknown Facility

Spartanburg, South Carolina, United States

Location

Unknown Facility

Amarillo, Texas, United States

Location

Unknown Facility

Arlington, Texas, United States

Location

Unknown Facility

Austin, Texas, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

Denton, Texas, United States

Location

Unknown Facility

Midland, Texas, United States

Location

Unknown Facility

Paris, Texas, United States

Location

Unknown Facility

Webster, Texas, United States

Location

Unknown Facility

Fairfax, Virginia, United States

Location

Unknown Facility

Norfolk, Virginia, United States

Location

Unknown Facility

Kennewick, Washington, United States

Location

Unknown Facility

Vancouver, Washington, United States

Location

Unknown Facility

Barnaul, Russia

Location

Unknown Facility

Engel's, Russia

Location

Unknown Facility

Kazan', Russia

Location

Unknown Facility

Kursk, Russia

Location

Unknown Facility

Kuzmolovsky, Russia

Location

Unknown Facility

Moscow, Russia

Location

Unknown Facility

Saint Petersburg, Russia

Location

Unknown Facility

Sochi, Russia

Location

Unknown Facility

Stavropol, Russia

Location

Unknown Facility

Voronezh, Russia

Location

Unknown Facility

Yekaterinburg, Russia

Location

Related Publications (1)

• O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011 Oct 7;10:126. doi: 10.1186/1476-4598-10-126.

  PMID: 21982118 DERIVED

MeSH Terms

Conditions

Prostatic Neoplasms; Neoplasm Metastasis; Disease

Interventions

gossypol acetic acid; Prednisone; Docetaxel

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Lance Leopold, MD

  Ascenta Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: December 11, 2007
• First Posted: December 12, 2007
• Study Start: October 1, 2007
• Primary Completion: September 1, 2010
• Study Completion: September 1, 2010
• Last Updated: November 9, 2010

Record last verified: 2010-11

Locations

US (24); RU (11)